← All trials
NCT04646109
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 11, 2020
- Primary completion
- Sep 2, 2020
- Completion date
- Sep 2, 2020
- First posted
- Nov 27, 2020
- Last posted
- Nov 27, 2020
- Enrollment
- 60
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Afyonkarahisar Health Sciences UniversityLead sponsor
- Afyonkarahisar Health Sciences UniversityReponsible party - principal investigator
- Afyonkarahisar Health Sciences UniversityStudy chair
- Afyonkarahisar Health Sciences UniversityStudy director
- Ankara Yildirim Beyazıt UniversityStudy director
- University of Health Sciences, TurkeyStudy director
- Sultan Abdulhamid Han Training and Research Hospital, Istanbul, TurkeyStudy director
- NeuTec PharmaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.